NCT05476575

Brief Summary

To understand the impact of perioperative hydrogen inhalation on post-operative pain control and serum inflammation markers

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
37

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 27, 2021

Completed
1 day until next milestone

Study Start

First participant enrolled

October 28, 2021

Completed
9 months until next milestone

First Posted

Study publicly available on registry

July 27, 2022

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2025

Completed
Last Updated

February 17, 2026

Status Verified

February 1, 2025

Enrollment Period

3.2 years

First QC Date

October 27, 2021

Last Update Submit

February 12, 2026

Conditions

Keywords

painhydrogen inhalationdiscectomy

Outcome Measures

Primary Outcomes (5)

  • Post-operative pain

    Post-operative pain, measured in visual analogue scale (VAS)

    immediately post-operative compared to pre-operative pain score measured in VAS

  • Post-operative pain

    Post-operative pain, measured in visual analogue scale (VAS)

    12 hours after operation compared to pre-operative pain score measured in VAS

  • Post-operative pain

    Post-operative pain, measured in visual analogue scale (VAS)

    24 hours after operation compared to pre-operative pain score measured in VAS

  • Post-operative pain

    Post-operative pain, measured in visual analogue scale (VAS)

    1 week after operation compared to pre-operative pain score measured in VAS

  • Post-operative pain

    Post-operative pain, measured in visual analogue scale (VAS)

    1 month after operation compared to pre-operative pain score measured in VAS

Secondary Outcomes (4)

  • Inflammation marker, Interleukin-6

    immediate post-operation compared to pre-operation

  • Inflammation marker, Interleukin-10

    immediate post-operation compared to pre-operation

  • Inflammation marker, Tumor necrotic factor-alpha

    immediate post-operation compared to pre-operation

  • Inflammation marker, Interleukin-1 beta

    immediate post-operation compared to pre-operation

Study Arms (2)

Hydrogen inhalation group

EXPERIMENTAL

Patients allocating to this group received hydrogen inhalation (4% hydrogen given via nasal cannula) with other normal intraoperative care throughout the whole procedure.

Other: hydrogen inhalation, 4% concentration, given via nasal cannula

Traditional care group

NO INTERVENTION

Patients allocating to this group received traditional intraoperative care.

Interventions

4% hydrogen inhalation via nasal cannula perioperatively

Hydrogen inhalation group

Eligibility Criteria

Age20 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient with herniated disc leading to severe neuropathic pain refractory to conservative treatment, receiving endoscopic discectomy.

You may not qualify if:

  • American Society of Anesthesiologists class IV or above
  • Sever impairment of heart, lung, kidney and liver and autoimmune disease
  • Less than 20 years old or older than 75 years old
  • Patient refusal
  • Severe complication occurring perioperatively
  • Current pregnancy
  • Hemoglobin less than 10g/dL.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fu Jen Catholic University Hospital

New Taipei City, 24300, Taiwan

Location

Related Publications (21)

  • Ge L, Yang M, Yang NN, Yin XX, Song WG. Molecular hydrogen: a preventive and therapeutic medical gas for various diseases. Oncotarget. 2017 Sep 21;8(60):102653-102673. doi: 10.18632/oncotarget.21130. eCollection 2017 Nov 24.

    PMID: 29254278BACKGROUND
  • Dole M, Wilson FR, Fife WP. Hyperbaric hydrogen therapy: a possible treatment for cancer. Science. 1975 Oct 10;190(4210):152-4. doi: 10.1126/science.1166304.

    PMID: 1166304BACKGROUND
  • Gharib B, Hanna S, Abdallahi OM, Lepidi H, Gardette B, De Reggi M. Anti-inflammatory properties of molecular hydrogen: investigation on parasite-induced liver inflammation. C R Acad Sci III. 2001 Aug;324(8):719-24. doi: 10.1016/s0764-4469(01)01350-6.

    PMID: 11510417BACKGROUND
  • Ohsawa I, Ishikawa M, Takahashi K, Watanabe M, Nishimaki K, Yamagata K, Katsura K, Katayama Y, Asoh S, Ohta S. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med. 2007 Jun;13(6):688-94. doi: 10.1038/nm1577. Epub 2007 May 7.

    PMID: 17486089BACKGROUND
  • Zhang DQ, Feng H, Chen WC. Effects of hydrogen-rich saline on taurocholate-induced acute pancreatitis in rat. Evid Based Complement Alternat Med. 2013;2013:731932. doi: 10.1155/2013/731932. Epub 2013 Jul 28.

    PMID: 23983797BACKGROUND
  • Hou Z, Luo W, Sun X, Hao S, Zhang Y, Xu F, Wang Z, Liu B. Hydrogen-rich saline protects against oxidative damage and cognitive deficits after mild traumatic brain injury. Brain Res Bull. 2012 Sep 1;88(6):560-5. doi: 10.1016/j.brainresbull.2012.06.006. Epub 2012 Jun 26.

    PMID: 22742936BACKGROUND
  • Xie K, Yu Y, Huang Y, Zheng L, Li J, Chen H, Han H, Hou L, Gong G, Wang G. Molecular hydrogen ameliorates lipopolysaccharide-induced acute lung injury in mice through reducing inflammation and apoptosis. Shock. 2012 May;37(5):548-55. doi: 10.1097/SHK.0b013e31824ddc81.

    PMID: 22508291BACKGROUND
  • Xin Y, Liu H, Zhang P, Chang L, Xie K. Molecular hydrogen inhalation attenuates postoperative cognitive impairment in rats. Neuroreport. 2017 Aug 2;28(11):694-700. doi: 10.1097/WNR.0000000000000824.

    PMID: 28614179BACKGROUND
  • Zhou H, Fu Z, Wei Y, Liu J, Cui X, Yang W, Ding W, Pan P, Li W. Hydrogen inhalation decreases lung graft injury in brain-dead donor rats. J Heart Lung Transplant. 2013 Feb;32(2):251-8. doi: 10.1016/j.healun.2012.11.007. Epub 2012 Dec 28.

    PMID: 23273744BACKGROUND
  • Ono H, Nishijima Y, Ohta S, Sakamoto M, Kinone K, Horikosi T, Tamaki M, Takeshita H, Futatuki T, Ohishi W, Ishiguro T, Okamoto S, Ishii S, Takanami H. Hydrogen Gas Inhalation Treatment in Acute Cerebral Infarction: A Randomized Controlled Clinical Study on Safety and Neuroprotection. J Stroke Cerebrovasc Dis. 2017 Nov;26(11):2587-2594. doi: 10.1016/j.jstrokecerebrovasdis.2017.06.012. Epub 2017 Jun 29.

    PMID: 28669654BACKGROUND
  • Fontanari P, Badier M, Guillot C, Tomei C, Burnet H, Gardette B, Jammes Y. Changes in maximal performance of inspiratory and skeletal muscles during and after the 7.1-MPa Hydra 10 record human dive. Eur J Appl Physiol. 2000 Mar;81(4):325-8. doi: 10.1007/s004210050050.

    PMID: 10664092BACKGROUND
  • Lillo RS, Parker EC, Porter WR. Decompression comparison of helium and hydrogen in rats. J Appl Physiol (1985). 1997 Mar;82(3):892-901. doi: 10.1152/jappl.1997.82.3.892.

    PMID: 9074979BACKGROUND
  • Abraini JH, Gardette-Chauffour MC, Martinez E, Rostain JC, Lemaire C. Psychophysiological reactions in humans during an open sea dive to 500 m with a hydrogen-helium-oxygen mixture. J Appl Physiol (1985). 1994 Mar;76(3):1113-8. doi: 10.1152/jappl.1994.76.3.1113.

    PMID: 8005852BACKGROUND
  • Kwok YH, Hutchinson MR, Gentgall MG, Rolan PE. Increased responsiveness of peripheral blood mononuclear cells to in vitro TLR 2, 4 and 7 ligand stimulation in chronic pain patients. PLoS One. 2012;7(8):e44232. doi: 10.1371/journal.pone.0044232. Epub 2012 Aug 28.

    PMID: 22937165BACKGROUND
  • Zhao J, Bi W, Xiao S, Lan X, Cheng X, Zhang J, Lu D, Wei W, Wang Y, Li H, Fu Y, Zhu L. Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice. Sci Rep. 2019 Apr 8;9(1):5790. doi: 10.1038/s41598-019-42286-8.

    PMID: 30962497BACKGROUND
  • Boucher Y, Moreau N, Mauborgne A, Dieb W. Lipopolysaccharide-mediated inflammatory priming potentiates painful post-traumatic trigeminal neuropathy. Physiol Behav. 2018 Oct 1;194:497-504. doi: 10.1016/j.physbeh.2018.06.021. Epub 2018 Jun 19.

    PMID: 29928887BACKGROUND
  • Hsieh CT, Lee YJ, Dai X, Ojeda NB, Lee HJ, Tien LT, Fan LW. Systemic Lipopolysaccharide-Induced Pain Sensitivity and Spinal Inflammation Were Reduced by Minocycline in Neonatal Rats. Int J Mol Sci. 2018 Sep 27;19(10):2947. doi: 10.3390/ijms19102947.

    PMID: 30262747BACKGROUND
  • Wang C, Song S, Zhang Y, Ge Y, Fang X, Huang T, Du J, Gao J. Inhibition of the Rho/Rho kinase pathway prevents lipopolysaccharide-induced hyperalgesia and the release of TNF-alpha and IL-1beta in the mouse spinal cord. Sci Rep. 2015 Sep 29;5:14553. doi: 10.1038/srep14553.

    PMID: 26416580BACKGROUND
  • Ramirez-Perez S, Hernandez-Palma LA, Oregon-Romero E, Anaya-Macias BU, Garcia-Arellano S, Gonzalez-Estevez G, Munoz-Valle JF. Downregulation of Inflammatory Cytokine Release from IL-1beta and LPS-Stimulated PBMC Orchestrated by ST2825, a MyD88 Dimerisation Inhibitor. Molecules. 2020 Sep 21;25(18):4322. doi: 10.3390/molecules25184322.

    PMID: 32967164BACKGROUND
  • Kida K, Marutani E, Nguyen RK, Ichinose F. Inhaled hydrogen sulfide prevents neuropathic pain after peripheral nerve injury in mice. Nitric Oxide. 2015 Apr 30;46:87-92. doi: 10.1016/j.niox.2014.11.014. Epub 2014 Nov 24.

    PMID: 25461302BACKGROUND
  • Kawaguchi M, Satoh Y, Otsubo Y, Kazama T. Molecular hydrogen attenuates neuropathic pain in mice. PLoS One. 2014 Jun 18;9(6):e100352. doi: 10.1371/journal.pone.0100352. eCollection 2014.

    PMID: 24941001BACKGROUND

MeSH Terms

Conditions

Acute PainPain

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Prospective case control study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 27, 2021

First Posted

July 27, 2022

Study Start

October 28, 2021

Primary Completion

December 30, 2024

Study Completion

February 28, 2025

Last Updated

February 17, 2026

Record last verified: 2025-02

Locations